Deep functional changes occurring within the endometrium during implantation are orchestrated by embryonic and maternal signals. Human chorionic gonadotropin (hCG), a major embryonic signal, plays a critical role in the initiation and maintenance of pregnancy. Interleukin (IL) 1, one of the earliest embryonic signals, appears to exert a direct impact on the receptive endometrium and to induce major molecular changes that are essential for embryo implantation. Herein we investigate whether hCG can modulate endometrial stromal cell (ESC) receptivity to IL1 during the implantation window and assess the impact on angiogenesis in vitro. Primary cultures of ESCs from normal fertile women during the implantation window were treated for 24 h with different concentrations of hCG (0-100 ng/ ml) and stimulated for 24 h with IL1B (0-0.1 ng/ml). IL1 receptors (IL1Rs), IL1R antagonist (IL1RA), and monocyte chemotactic protein (MCP) 1 were analyzed by real-time PCR, ELISA, and Western blotting. The angiogenic activity in vitro was studied using human microvascular endothelial cell line, scratch wound assay, and cell proliferation via BrdU incorporation into DNA. Human CG induced a dose-dependent imbalance in ESC receptivity to IL1 by significantly upregulating the functional signaling IL1R1 and concomitantly downregulating the decoy inhibitory IL1R2 and IL1RA upon subsequent exposure to IL1B. Prior exposure to hCG amplified MCP1 secretion by ESCs in response to IL1B and triggered the release of angiogenic activity in vitro in which MCP1 appeared to play a significant role. Overexpression of IL1R2 using cell transfection inhibited IL1 and hCG/IL1B-mediated MCP1 secretion. These findings suggest that hCG coordinates embryonic signal interaction with the maternal endometrium, and point to a new possible pathway by which it may promote embryonic growth.
INTRODUCTION
Successful blastocyst implantation requires precise synchronization between the embryo and the uterine environment. The endometrium is a specialized, hormonally regulated organ that does not adhere to embryos throughout most of the menstrual cycle in human as well as other mammals [1] .
The endometrium acquires a receptive phenotype to the embryo during a special, limited period of the menstrual cycle called the ''implantation window,'' through specific structural and functional changes allowing blastocyst adhesion. Estradiol induces endometrial tissue proliferation, which is followed by progesterone-induced differentiation and the establishment of an implantation window [2] . This appears to occur between Days 19 and 24 of the menstrual cycle in humans. The dynamics of this transition from a nonreceptive to a receptive endometrium are poorly understood, but the correct spatiotemporal synthesis and balance of various factors regulated by steroid hormones is thought to play an important role in uterine preparation for implantation [3] [4] [5] [6] [7] .
During this crucial period, numerous cytokines and growth factors are produced by both the preimplanted embryo and the uterine microenvironment [8] . In this intricate network of interactions involved in embryo implantation, cytokines and other hormonal factors act as mediators for maternal-fetal cross-talk. In this study, we addressed the interaction between two early embryonic signals: human chorionic gonadotropin (hCG) and interleukin (IL) 1.
Human CG is a major embryonic signal that plays a critical role in the initiation and maintenance of pregnancy [9] . Human CG acts on the intrauterine environment via the luteinizing hormone (LH)/hCG receptor (hLHCGR). Human endometrium, the natural host site where the embryo implants and develops, has been shown to contain functional membranebound hLHCGRs (mb-hLHCGRs), which have been detected in glandular and luminal epithelial cells, as well as in stromal cells [10, 11] . At the time of implantation, hCG has been shown to be involved in a wide spectrum of cell targets and biological actions. Synthesized early by the trophoblast, hCG appeared to influence endometrial receptivity and implantation [9] , promote the decidualization of human endometrial stromal cells (ESCs) [12] , and to possess both direct and indirect angiogenic properties [13] [14] [15] .
IL1 is one of the earliest embryonic signals. Human embryos cultured in vitro produce high concentrations of IL1A and IL1B, and the presence of these cytokines has been correlated with successful implantation after transfer to the uterine cavity [16] . The IL1 system is composed of two agonists (IL1A and IL1B), one inhibitor (i.e., the IL1 receptor [IL1R] antagonist [IL1RA]), and two receptors (IL1R1 and IL1R2). IL1B is the circulating form of IL1, and IL1A is the membrane-bound form. Both IL1B and IL1A activate IL1R1 and exert similar effects, but IL1B has more affinity for IL1R2 [17] . IL1R1 acts as functional receptor and can transduce a signal upon IL1 binding, with the recruitment of a second subunit, termed IL1 accessory protein (IL1 RACP or IL1R3) [18] . IL1R2 rather acts as a negative regulator (or antagonist) of IL1 action and has been termed a ''decoy receptor'' [19] . Expression of functional IL1R1 has been detected throughout endometrial tissue, but is only moderately upregulated during the luteal phase [20] . Expression of the decoy IL1R2 follows a regulated cycle phase-dependent pattern. Thus, IL1R2 first increases in the midproliferative phase, decreases at the time of implantation, and then increases again in the late secretory phase [21] . Secretion of embryonic IL1B in response to the receptive endometrium might induce molecular changes that are essential for embryonic implantation. Our first studies had revealed that hCG downregulates the expression of the decoy antagonist IL1R2 in endometrial epithelial cells without affecting the expression of the functional activating receptor type I (IL1R1) [22] . This points to a possible mechanism by which hCG could modulate endometrial receptivity to IL1B at the time of implantation.
The objective of the present study was to investigate whether hCG can target human ESCs during the implantation window to modulate cell responsiveness to IL1, and assess the possible impact on angiogenesis in vitro. Herein we show that hCG creates a significant imbalance in IL1Rs expression, amplifies cell responsiveness to ILB, and leads to a significant increase in monocyte chemotactic protein (MCP)-1 secretion and the release of angiogenic activity in vitro in which MCP1 appears to play a significant role. In view of the role of IL1 as a major and early embryonic signal, the present data point to a potentially novel mechanism by which hCG sustains human pregnancy and promotes embryonic growth.
MATERIALS AND METHODS

Subjects and Tissue Handling
Endometrial tissue specimens were obtained during the implantation window (Days 19-24) from normal fertile women with a regular menstrual cycle, who were undergoing laparoscopy for tubal ligation and had not received hormonal or anti-inflammatory therapy for at least 3 mo prior to surgery (mean age 6 SD, 35.6 6 4.9 yr; n ¼ 7). Menstrual cycle day was determined according to the histological criteria of Noyes et al. [23] . Written informed consent was obtained from participants under a study protocol approved by the Ethics Committee on Human Research at Laval University, Quebec, Canada. Endometrial tissue was immediately placed in cold, sterile Hanks balanced salt solution (HBSS) (Invitrogen Life Technologies, Burlington, ON, Canada) containing 1% antibiotics, then directly transported to the laboratory. A part of the biopsy was taken for cell culture.
Cell Culture and Treatment
Biopsies used in this study were devoid of any visible blood contamination. Tissues were immediately washed with cold HBSS and ESCs were isolated and cultured at 378C, 5% CO 2 , in Dulbecco modified Eagle medium (DMEM):F12 (1:1) containing 10% charcoal-treated fetal bovine serum (FBS), insulin, transferrin, and a mix of antibiotics-antimycotics according to our previously described procedure [24] . ESCs prepared using this protocol were vimentin positive and found to be free of cytokeratin-positive epithelial cells, von Willbrand factor-positive endothelial cells, or CD45-positive leukocytes [24] , and used between passages 1 and 3. At preconfluence, cells were incubated overnight with phenol and FBS-free medium and treated with hCG (0-1000 ng/ ml; Sigma-Aldrich Co., St. Louis, MO) for 24 h. Cells were then stimulated with IL1B (0-1 ng/ml; R&D Systems, Minneapolis, MN) for 24 h and culture supernatants were recovered, centrifuged to eliminate cell debris, and divided into small aliquots; cells were trypsinized and collected and both supernatants, and cells were stored at À808C until further use.
Real-Time PCR
Total RNA was extracted with TRIzol (Invitrogen), reverse transcribed, and analyzed by quantitative real-time RT-PCR (qRT-PCR), according to a previously reported procedure [25] . Following a 958C denaturation for 2 min, the reactions were cycled 40 times with denaturation at 958C for 15 0 -CAGGGCTGCTTTTAACTCTGG-3 0 ; reverse, 5 0 -TGGGTGGAATCATATTGGAACA; amplimer size, 102 bp) were designed with Primer Express version 2.0 (Applied Biosystems), spanned intron-exon boundaries to avoid amplification of genomic DNA, and were selected for melting temperature (Tm) value compatibility (57-618C). For each experimental sample, IL1R1, IL1R2, and MCP1 mRNA levels were normalized to GAPDH mRNA levels. Quantification of IL1R1, IL1R2, and IL1RA mRNA was performed using a relative quantification method. After each run, melting curve analysis (55-958C) was performed to verify the specificity of the PCR. All samples were tested in duplicate, each run including a no-reverse transcription control.
Western Blot Analysis
Proteins were extracted from cultured cells in a buffer containing 0.5% Triton-X100, 10 mM Hepes (pH 7.4), 150 mM NaCl, 2 mM ethylene glycol tetraacetic acid, 2 mM ethylene diamine tetraacetic acid, 0.05% NaN3, and a mixture of antiproteases, composed of 5 lM aprotinin, 63 lM leupeptin, and 3 mM phenylmethylsulfonylfluoride. Cell homogenate was then incubated at 48C for 45 min under gentle shaking and centrifuged at 11 000 3 g for 30 min to recover the soluble extract. Total protein concentration was determined using Bio-Rad DC Protein Assay (Bio-Rad Laboratories, Mississauga, ON, Canada). Protein extracts (10 lg) were then separated by SDS-PAGE, transferred onto 0.45-lm nitrocellulose membranes, and analyzed by Western blotting, as described previously [26, 27] . Briefly, IL1R1 and IL1R2 were detected using specific goat polyclonal antibodies (1:100 dilution in PBS containing 5% skim milk and 0.1% Tween 20 [blocking solution]; R&D systems), while IL1RA was detected using a specific rabbit polyclonal antibody (Genzyme). Fc-specific peroxidase-labeled rabbit anti-goat antibody (1:10 000 in blocking solution; Jackson ImmunoResearch Laboratories, Inc., West Grove, PA) was then used for IL1R1 and IL1R2, whereas an Fcspecific peroxidase-labeled goat anti-rabbit antibody (1:150 000 in blocking solution; Jackson ImmunoResearch Laboratories) was used for IL1RA. ECL reagent (GE Healthcare, Chalfont St. Giles, UK) and exposure to Super-RX films (Fuji, Tokyo, Japan) for 5-30 min for optimal detection (all bands visible, but not overexposed). Controls included incubation with equivalent concentrations of normal goat (IL1R1 and IL1R2) and rabbit (IL1RA) IgGs. Membranes were stripped and reblotted with a monoclonal antibody specific to a-actin (1:50 000 dilution in PBS-0.01% Tween-20; Sigma-Aldrich Co.) used as internal control for protein loading and transfer.
Cell Transfection
Cells were seeded into 24-well plates and grown until 70% confluence. Cells were then transfected with the eukaryotic expression vector pcDNA3 either alone or containing a cDNA coding for IL1R2 [28] . Transfection was performed using Lipofectamine Plus reagent according to manufacturer's instructions (Life Technologies Inc.) and our previously described procedure [26] . Cells were exposed for 24 h to the minimal culture medium (MM) alone or containing hCG (100 ng/ml), IL1B (0.1 ng/ml) or hCG/IL1B (100/0.1 ng/ ml). The culture supernatants were then collected and kept in small aliquots at À808C until use by ELISA.
Enzyme-Linked Immunosorbent Assay
MCP1, soluble (s) IL1R2, and IL1RA concentrations in the culture medium were measured using previously reported sandwich ELISAs [27, 29] .
Scratch Wound Assay
In this study, we used a human microvascular endothelial cell (HMVEC) line. This line of immortalizing primary HMVECs was generated by engineering the human telomerase catalytic protein. Cells were shown to maintain inherent features of primary endothelial cells and to produce BOURDIEC ET AL.
angiogenic response [30] . Cells were seeded into 24-well plates and grown to confluence in MCDB 131 medium. Cell monolayers were carefully wounded with a 200-ll pipette tip to generate a cut of ;1 mm in width. After two washing steps, cells were incubated for 24 h under various positive control conditions (VEGF and FGF [R&D Systems], or MCP1 [Prospec, East Brunswick, NJ]) or ESC-conditioned medium (1:3 dilution in FBS-free DMEM-F12). MCP1 was neutralized in culture using a neutralizing MCP1 antibody (5 lg/ml; MAB 279; R&D Systems). Cells were then fixed with 10% formalin for 20 min, stained with 4 0 ,6-diamidino-2-phenylindole, and wound healing was determined by measuring scratch width at seven random locations along the wound to examine the extent of closure using fluorescence microscopy. Measures were performed in duplicate and repeated three times.
DNA Synthesis Assay by BrdU Incorporation
HMVECs were seeded in 96-well microtiter plates (1 3 10 4 cells/well), cultured overnight, starved for 48 h in DMEM-F12 containing 0.2% FBS, and incubated for 48 h with ESC-conditioned media from cultures treated with hCG (100 ng/ml), IL1 (0.1 ng/ml), and hCG (100 ng/ml)/IL1 (0.1 ng/ml), equivalent concentrations of hCG, IL1, and hCG/IL1 similarly diluted in MM, MCP1 (250 and 350 ng/ml, which correspond to the mean levels of MCP1 found in the culture medium following IL1 or hCG/IL1 stimulation), VEGF (25 and 50 ng/ ml), and FGF (25 and 50 ng/ml) (R&D Systems). For inhibitory assays, MCP1 was neutralized in culture with MCP1 antibody (5 lg/ml). After 24 h, cells were labeled with 10 lM BrdU for 24 h at 378C, and cell proliferation was assessed by ELISA according to the manufacturer's instructions (GE Healthcare, Mississauga, ON, Canada). Briefly, cells were fixed and genomic DNA was denatured by adding 200 ll/well of blocking reagent for 30 min at room temperature. Peroxidase-labeled anti-BrdU antibody was then added (100 ll/ well) and incubated for 90 min at room temperature. Wells were washed three times, 3,3 0 ,5,5 0 -tetramethylbenzidine substrate was added (100 ll/well) and incubated for 15 min at room temperature, and the optical density was measured at 450 nm.
Statistical Analysis
Three experiments were carried out for each result shown, and all measurements were performed in duplicate. Data followed a parametric distribution, and were expressed as means 6 SEM. The significance of statistical differences was determined using one-way ANOVA followed by the Boferroni test post hoc for multiple analyses, and the Student t-test for comparing two groups. All analyses were performed with GraphPad Prism 4.0 (GraphPad Software, Inc., San Diego, CA).
RESULTS
Human CG Regulates Expression of IL1Rs in ESCs
Cell cultures were exposed to different concentrations of hCG (0-100 ng/ml) for 24 h before being stimulated for 24 h with IL1B (0-0.1 ng/ml). As shown in Figure 1 , alone, each stimulus induced small and statistically nonsignificant variations of IL1R1 mRNA expression (Fig. 1A) . However, a pretreatment with hCG followed by IL1B (0.1 ng/ml) resulted in an induction of IL1R1 mRNA expression, which was statistically significant for 10 (P , 0.05) and 100 (P , 0.001) ng/ml hCG. Furthermore, as shown in Figure 1B , IL1B (0.1 ng/ ml) significantly upregulated IL1R2 mRNA expression in ESCs (P , 0.001), but pretreatment of cells with hCG (10 and 100 ng/ml) resulted in a significant downregulation of the IL1B-induced IL1R2 mRNA expression (P , 0.05 and P , 0.01, respectively). Furthermore, IL1B (0.1 ng/ml) significantly upregulated IL1RA mRNA expression in ESCs (P , 0.05). However, cell pretreatment with hCG (10 and 100 ng/ml) significantly downregulated the IL1B-induced IL1RA mRNA expression (P , 0.05; Fig. 1C) .
Western blot analysis of IL1R1 showed that treatment of ESCs with IL1B (1 ng/ml) increased the intensity of membrane (mb) and soluble (s) IL1R2 bands (68 and 45 kDa) and that of IL1RA (17k Da). However, cell pretreatment with hCG (100 ng/ml) decreased the IL1B-indued IL1R2 and IL1R2 expression, but appeared to increase the expression of mb and sIL1R1 ( Fig. 2A) . Naturally occurring sIL1Rs are released following natural proteolytic cleavage and shedding from the extracellular domain of mbIL1R's [31] [32] [33] . Soluble IL1R1 was not detectable in ESC culture supernatants. Conversely, sIL1R2 was measurable in the culture medium and found to be increased by IL1B (0.1 ng/ml) (P , 0.001), but decreased in cells pretreated with hCG (100 ng/ml) prior to ILB exposure (P , 0.001) (Fig. 2B) . Measurement of IL1RA showed comparable effects of IL1B which increased the antagonist concentration in the culture medium (P , 0.05), while prior treatment with hCG significantly decreased this IL1B-mediated IL1RA secretion (P , 0.05) (Fig. 2C) . Confluent ESC cultures were incubated with MM or hCG (10 and 100 ng/ ml) for 24 h before being exposed, or not, to IL1B (0.01 and 0.1 ng/ml) for an additional 24 h. Total RNA was extracted and reverse transcribed. IL1R1, IL1R2, IL1RA, and GAPDH (internal control) mRNA levels were quantified by real-time PCR, as described in Materials and Methods. IL1R1 (A), IL1R2 (B), and IL1RA (C) mRNA ratio was then determined following normalization to GAPDH mRNA. Data were from ESC cultures issued from three different subjects and expressed as percent of control (ratio of IL1R1, IL1R2, or IL1RA mRNA levels found in cells incubated with IL1B, hCG, or hCG/ILB to those found in cells incubated with the control culture medium [MM] for an equivalent period of time). *P , 0.05, ***P , 0.001 relative to MM; P , 0.05, P , 0.01 relative to cells stimulated with equivalent concentrations of IL1B.
hCG TRIGGERS ANGIOGENESIS VIA IL1 SIGNALING
ESCs Secrete High Concentrations of MCP1 in Response to Embryonic Stimuli
The data presented above show that hCG regulates the expression of IL1Rs 1 and 2 in an opposite, but functionally complementary, manner, and suggest that hCG amplifies the cellular response to this cytokine. In order to investigate this, we first assessed its impact on the synthesis and secretion levels of MCP1, one of the known IL1 signaling targets [34] . This chemokine is responsible for monocyte trafficking and activation, and has been recognized as a potent tissue   FIG. 2 . Human CG modulates the expression of the protein of IL1R in ESCs. Confluent ESC cultures were incubated with MM or 100 ng/ml hCG for 24 h before being exposed, or not, to IL1B (0.1 ng/ml) for an additional 24 h. Cells were recovered to extract total proteins and analyze IL1R1, IL1R2, and IL1RA (A), and culture supernatants were collected to measure sIL1R2 (B) and IL1RA (C), as described in Materials and Methods. Data were from ESC cultures issued from three different subjects and expressed as percent of control (ratio of sIL1R2 or IL1RA levels found in cells incubated with IL1B, hCG, or hCG/ILB to those found in cells incubated with the control culture medium [MM] for an equivalent period of time). *P , 0.05, ***P , 0.001 relative to MM; P , 0.05, P , 0.001 relative to cells stimulated with equivalent concentrations of IL1B.
FIG. 3.
Human CG enhances MCP1 expression in ESCs in response to ILB. Confluent ESC cultures were incubated with MM or hCG (10 and 100 ng/ml) for 24 h before being exposed, or not, to IL1B (0.01 and 0.1 ng/ml) for an additional 24 h. Total cell RNA was extracted and reverse transcribed. MCP1, IL1R1, IL1R2, and GAPDH were quantified by realtime PCR, as described in Materials and Methods. MCP1 mRNA (A) and IL1R2:IL1R1 mRNA ratio (C) were then determined following normalization to GAPDH mRNA. The culture supernatants were recovered for determination of MCP1 secretion by ELISA (B). Data are from ESC cultures issued from three different subjects and expressed as percent of control (ratio of MCP1 mRNA levels or protein secretion in cells incubated with IL1B, hCG, or IL1B/hCG to those in cells incubated with the control minimal culture medium [MM] for an equivalent period of time). *P , 0.05, **P , 0.01, ***P , 0.001 relative to MM; P , 0.05, P , 0.01, P , 0.001 relative to IL1B control dose.
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remodeling and angiogenic factor [35] . Quantitative real-time PCR analysis showed a dose-dependent upregulation of MCP1 mRNA steady-state levels in response to IL1B (Fig. 3A) . Human CG had no significant effect on MCP1 mRNA. However, ESCs pretreated with 10 and 100 ng/ml hCG showed a significant stimulation of MCP1 mRNA expression in response to 0.01 (P , 0.01 and P , 0.001, respectively) and 0.10 (P , 0.001 and P , 0.001, respectively) ng/ml IL1B as compared with cells incubated with the culture medium alone, or with cells exposed to 0.01 (P , 0.05 and P , 0.01, respectively) and 0.1 (P , 0.05) ng/ml ILB without any prior hCG treatment. This suggests an hCG-mediated enhancement of ESC activation by IL1B (Fig. 3A) . Furthermore, analysis of MCP1 secretion in the culture medium showed a significant dose-dependent increase in response to IL1B (Fig. 3B ). Human CG alone had no significant effect on MCP1 secretion by ESCs. However, treatment with hCG followed by incubation with IL1B enhanced MCP1 secretion by ESCs. In fact, cell pretreatment with 10 and 100 ng/ml hCG significantly increased MCP1 concentration in the conditioned medium in response to 0.01 (P , 0.01) and 0.10 (P , 0.001 and P , 0.01, respectively) ng/ml IL1B as compared with the culture medium, or to 0.01 (P , 0.01) and 0.1 (P , 0.01) ng/ml IL1B without any prior hCG treatment (Fig. 3B) . Determination of the ratio of IL1R2:IL1R1 mRNA expression in these cells showed that it increased in cells exposed to 0.01 and 0.1 ng/ml IL1B as compared with untreated cells (P , 0.05 and P , 0.01, respectively), but decreased in cells pretreated for 24 h with 10 (P , 0.05 and P , 0.01, respectively) and 100 (P , 0.05 and P , 0.001, respectively) ng/ml of hCG. Interestingly, the diminution of the IL1R2:IL1R1 ratio occurred in parallel with the increase in MCP1, either in cells exposed to hCG alone or in cells exposed to hCG prior to IL1B stimulation (Fig. 3C) . However, coincubation of ESCs with hCG and IL1B for 24 h without prior pretreatment with hCG significantly reduced the IL1-R2:IL1R1 ratio and increased MCP1 mRNA, but did not result in any significant increase in MCP1 protein secretion, suggesting that the hCG-mediated imbalance in IL1Rs occurs prior to the augmentation of MCP1 secretion (data not shown). ESCs were then assessed for MCP1 secretion in response to hCG, ILB, or hCG/ILB following transfection with the pcDNA3 expression vector alone (control) or containing IL1R2 cDNA. Cells transfected with the control expression vector showed a significant increase in MCP1 secretion in response to IL1B (0.1 ng/ml) and hCG (100 ng/ml)/ILB (0.1 ng/ml) (P , 0.05 and P , 0.001, respectively) as compared with the control medium. Furthermore, MCP1 secretion was significantly increased in cells stimulated with hCG/ILB compared with cells incubated with an equivalent concentration of IL1B (P , 0.01). However, cell transfection with IL1R2 cDNA dampened these effects and resulted in a significant decrease of hCG/IL1B-induced MCP1 production (P , 0.001; Fig. 4A ). It is noteworthy that sIL1R2 was noticeably upregulated in cells that were transfected with IL1R2 cDNA compared with pcDNA3 vector-transfected cells (Fig. 4B ).
MCP1 and Angiogenic Effects In Vitro of ESC-Conditioned Media
In view of the significant increase in the IL1-induced MCP1 secretion caused by priming ESCs with hCG, we next addressed the hypothesis that medium conditioned by ESCs upon such exposure to these two embryonic signals might possess angiogenic activity. We thus examined the potential of conditioned ESC medium to induce angiogenic activity in vitro using the scratch wound assay. As shown in Figure 5A , conditioned media from hCG-treated ESC cultures significantly induced HMVEC scratch closure (P , 0.05). Moreover, when HMVECs were exposed to medium conditioned by ESCs sequentially stimulated with hCG (100 ng/ml), then with 0.01 or 0.1 ng/ml IL1B, a significant dose-dependent closure of the scratch was observed compared with the culture medium (P , 0.01), hCG (P , 0.05), or IL1B (P , 0.01 and P , 0.05, respectively). Meanwhile, no significant effect of controls (hCG, IL1B, or hCG/ILB used at equivalent concentrations) on HMVEC scratch closure was noted (Fig. 5B) .
To evaluate whether MCP1 detected in media conditioned by ESCs exhibit angiogenic activities in vitro, we used a blocking monoclonal antibody (MAB-279) (5 lg/ml) against human MCP1. Medium conditioned by ESCs sequentially stimulated with hCG and IL1B was incubated with the MCP1 antibody for 1 h at room temperature before being added to endothelial cell cultures for 24 h. HMVECs treated with recombinant human (rh) MCP1 (250 ng/ml), FGF (250 ng/ml), or VEGF (250 ng/ml) as positive controls showed a significant closure of the scratch (P , 0.01, P , 0.05, and P , 0.05, respectively) (Fig. 6, A and B) . Further analysis showed a significant decrease in wound closure when rhMCP1 (P , 0.05) or hCG/IL1B-treated cell conditioned media were preincubated with anti-MCP1 antibody (P , 0.001 and P , 0.01).
FIG. 4.
Overexpression of IL1R2 using cell transfection decreases of IL1B-and hCG/IL1B-induced MCP1 production by ESCs. Cells were transiently transfected with pcDNA3-IL1R2 or with the control vector pcDNA3 and incubated for 24 h with MM, hCG (100 ng/ml), IL1B (0.1 ng/ ml), or hCG/IL1B (100/0.1 ng/ml), and MCP1 (A) and sIL1R2 (B) production was measured in the culture medium by ELISA. *P , 0.05, **P , 0.01, ***P , 0.001 relative to MM; P , 0.05, P , 0.001 relative to IL1B control dose; hCG TRIGGERS ANGIOGENESIS VIA IL1 SIGNALING Importantly, the IgG control had no significant effect on scratch closure (Fig. 6, C and D ). These data demonstrate that HMVECs migrate in response to rhMCP1, as well as to MCP1 secreted by ESCs in response to hCG and IL1B.
One essential component of angiogenesis is endothelial cell proliferation. We thus performed BrdU incorporation assays under conditions similar to the scratch tests reported above. Like positive controls (i.e., direct addition of rhMCP1 [250 and 350 ng/ml], FGF [25 and 50 ng/ml], or VEGF [25 and 50 ng/ ml]), conditioned media from ESCs treated with 100 ng/ml hCG, 0.1 ng/ml IL1B, or a combination of these two factors induced a significant increase in BrdU incorporation into endothelial cell DNA (Fig. 7A) , whereas hCG, IL1B, and hCG/ ILB used at equivalent concentrations had no significant effect (Fig. 7B) . Furthermore, MAB-279 inhibited the conditioned medium-induced BrdU incorporation into HMVEC DNA (Fig.  7C) . The latter two tests provide support for the hypothesis that hCG and IL1B may exert a combined stimulatory effect on angiogenesis, as observed in vitro using endothelial cell migration and proliferation and schematized in Figure 8 .
DISCUSSION
Similarly to other key embryonic signals, such as hCG, IL1 triggers a cascade of intricate events at the fetomaternal interface, which facilitate embryonic implantation and growth within endometrial host tissue [9, 22] . Accordingly, it is not surprising to see elaborate mechanisms operating locally at the level of the cytokine's targets, which tightly regulate and counter-regulate the biological effects of IL1 in order to ensure normal reproductive functions.
In the present study, we showed that hCG is able to modulate IL1B receptivity in primary ESCs during the implantation window. Curiously, hCG alone had no significant effect on IL1R1 or IL1R2 expression. However, it appeared to counterbalance the IL1-induced increase in IL1R2 and IL1RA and further enhance the IL1-induced increase in IL1R1, thereby decreasing the IL1R2:IL1R1 ratio. IL1R1 is a signaling functional receptor, whereas IL1R2, which has no signaling properties, rather acts as a decoy receptor that captures IL1 and prevents its effects on target cells [19] . Therefore, these opposite, but functionally complementary, effects of hCG on the expression of IL1Rs create an imbalance in ESC receptivity to IL1, which may favor cell responsiveness and amplify IL1-induced cell activation.
It is noteworthy that hCG per se had a significant downregulatory effect on ILR2 expression in endometrial epithelial cells [22] . The reasons for such an endometrial cell type-dependent difference in hCG action remains unknown, but it is of interest that, according to our previous studies [21] , endometrial epithelial cells display a higher expression level of ILR2 than stromal cells which may explain the detectable effect of hCG on these cells.
In the present study, we assessed the possible impact of hCG-mediated changes in the expression of IL1Rs in ESCs on the release of MCP1. Our data showed a significant hCGmediated amplification of ESC responsiveness to IL1B and an upregulation of MCP1 transcripts. In order to determine whether this may also occur at the protein level, analysis of ESC supernatant showed that prior treatment with hCG leads to a significant augmentation of the IL1B-induced MCP1 protein secretion as well. These observations are clearly consistent with the changes in ESC receptivity to IL1B that follow hCG treatment [36] . In addition, the observation of a substantial increase in MCP1 secretion (2000% to 4500% of control) under regulation by hCG and IL1B may be particularly interesting in view of previous studies finding MCP1 in the category of genes that become upregulated in ESCs upon exposure to embryonic stimuli [37, 38] and the biological properties of this factor. MCP1 was named for its capability to chemoattract monocytes, but is also known for its potent growth-promoting and angiogenic properties [36, 39] . MCP1 has been implicated in angiogenesis as a direct as well as indirect proangiogenic factor. Indirectly, MCP1 acts on various cell types in inducing the secretion of proangiogenic molecules [40] . MCP1 can also act directly on endothelial cells to induce ) following ESC treatment with hCG (100 ng/ml) and IL1B (0.01 and 0.1 ng/ml), as described in Figures 1 and 2 . ESC-conditioned media were used at 1:3 dilution in MM (A), and hCG (100 ng/ml), IL1 (0.01 and 0.1 ng/ml), and hCG/IL1 combinations were similarly diluted (1:3 in MM) and included as controls (B). Cell migration to the wound surface was quantified by microscopy at 43 magnification. Data are from ESC cultures issued from three different subjects and expressed as percent of closure. *P , 0.05, **P , 0.01 relative to MM; P , 0.05 relative to hCG control dose; þ P , 0.05, þþ P , 0.01 relative to IL1B control dose.
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angiogenesis [36] . However, the mechanism by which MCP1 mediates these effects on angiogenesis is poorly understood.
The recently identified MCP1-induced protein enhances endothelial cell proliferation, migration, and expression of angiogenesis-related genes, resulting in capillary-like tube formation. The role of MCP1 in monocyte/macrophage recruitment and activation is of relevance as well for embryonic implantation and growth. Actually, macrophages were shown to contribute to decidualization and implantation, and to remain present at high levels at the implantation site throughout pregnancy [41, 42] . Instead of impairing the growth of the semiallogeneic embryo, uterine macrophages rather appeared to maintain immune tolerance toward trophoblastic antigens, favor embryonic cell proliferation, mediate the extent of trophoblast invasion, and play a protective role against possible infections. Interestingly, the available literature suggests that trophoblastic cells regulate monocyte migration and differentiation to create an adequate environment to promote trophoblast growth and survival and modulate monocyte response to bacterial stimuli. This strengthens the relevance of our findings and broadens the spectrum of the impact of hCG on early embryonic growth and development. hCG TRIGGERS ANGIOGENESIS VIA IL1 SIGNALING
The available literature supports a role for IL1 in embryo implantation. Simon et al. [43] demonstrated that IL1R1 mRNA is upregulated by its ligand IL1B in ESCs isolated during the luteal phase, and suggested a role for the IL1 system in human implantation. Using a mouse model, these authors further showed that blastocysts did not attach or implant in IL1RA-treated animals, suggesting that blockade of IL1R1 interferes with the attachment of mouse blastocysts to maternal endometrium [44] . Furthermore, IL1RA appeared to act on the endometrial epithelium by inhibiting epithelial plasma membrane transformation at the time of implantation, presumably via transcriptional downregulation of a4 and posttranscriptional decrease of av and b3 integrin subunits [45] .
To characterize the angiogenic activity in vitro of conditioned media, we used HMVECs as a model [30] . The line was immortalized by engineering the human telomerase catalytic protein and found to generate a prominent angiogenic response in vitro [46] . Using the in vitro scratch wound assay, our data showed a significant stimulatory effect of hCG and IL1B on the capability of ESC-conditioned media to favor HMVEC scratch wound healing and a significant involvement of MCP1 secreted by ESCs. Assessment of HMVEC proliferation via the incorporation of BRdU into cell DNA revealed a similar action. This strongly suggests that the modulation of endometrial cell receptivity to ILB in response to hCG may translate into increased cell responsiveness to IL1B and potentiate the secretion of angiogenic factors. Nevertheless, factors other than MCP1 may contribute to the detected angiogenic activity, as the reduction of BrdU incorporation by MCP1 antibody was partial and the closure was significantly induced by supernatant from stromal cells solely treated by hCG, although MCP1 was not induced by hCG alone. Investigations are underway in order to identify the other possible angiogenic factors that mediate hCG, IL1B, and/ or hCG/IL1B effects. (10 4 cells/well in 96-well microtiter plates) were cultured overnight, starved in DMEM-F12 containing 0.2% FBS, and incubated with MCP1, VEGF, and FGF (positive controls), and ESCconditioned media (1:3 dilution in MM) from cultures treated with hCG (100 ng/ml), IL1 (0.1 ng/ml), and hCG (100 ng/ml)/IL1 (0.1 ng/ml) (A) or with equivalent concentrations of hCG, IL1, and hCG/IL1 similarly diluted in MM (B). MCP1 was neutralized in ESC-conditioned media with anti-MCP1 antibody (MAB 279) (C). Cell proliferation was assessed by ELISA using BrdU incorporation into HMVEC DNA. Data are from ESC cultures issued from three different subjects and expressed as percent of control (S-MM in A and C; MM in B). *P , 0.05, **P , 0.01, ***P , 0.001 as compared to control; P , 0.05 as compared to S-hCG100/MM; þ P , 0.05 as compared to S-MM/IL1B 0.1. 
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Because IL1R1 signal transduction requires IL1 accessory protein (IL1R3), future studies will also evaluate if IL1R3 is regulated by hCG in ESCs at time of implantation. Furthermore, it will be interesting to address the identification of other potential targets of hCG and IL1 involved in embryonic growth and development, and ultimately study the impact of possible related defects on infertility. Some infertility cases may result from diminished uterine receptivity or delayed implantation [47] . On the other hand, the incidence of pregnancy loss after implantation is high, estimated at 25%-40% [48] . Although many losses involve genetic abnormalities, there is often no known cause [49] . Hormonal factors, leukemia-inhibiting factor, and prostanoid pathways play an important role in successful implantation. However, given the complexity of early development, it is likely that many other mechanisms are also involved, and a better understanding of the mechanisms responsible for implantation is crucial.
In conclusion, this study reports, for the first time, a close interaction between IL1B and hCG in signaling to uterine stromal cells in vitro. Human CG appeared to amplify ESC receptivity/responsiveness to IL1B and to enhance (alter expression of IL1Rs and induce) the expression and release of MCP1, which is shown to have effects on the motility and proliferation of HMVECs. This is relevant to physiology of embryo implantation, as IL1B and hCG are both produced by embryos, and angiogenesis is an early uterine response to embryo implantation.
